CURRENT CLINICAL TRIALS UNDERWAY

Participation in a clinical trial can provide access to cutting-edge, potentially lifesaving and life-enhancing treatments.

The Queensland Eye Institute is currently looking for volunteer participants in the following clinical trails:  

Clinical Trial - Primary Sjögren’s Syndrome 

The Queensland Eye Institute is currently recruiting for patients with Primary Sjögren’s Syndrome.  It is a Phase I/IIa Study to evaluate the application of Placental Stem Cells for the treatment and management of Sjögren’s Syndrome. The aim of the trial is to see if the Placental Mesenchymal Stem/Stromal Cell (P-MSC) Therapy has a positive effect on the adaptive immune system and determine if the treatment helps to enable the regeneration of moisture-producing glands. Principal Investigator Dr Allison Sutherland and Dr Brendan Cronin

READ THE KEY INCLUSION CRITERIA FOR THE Primary Sjögren’s Syndrome STUDY



Clinical Trial Study - Diabetic Macular Oedema (DME)

The Queensland Eye Institute is currently recruiting for patients with macular oedema due to diabetic macular oedema (DME). It is a Phase 4 progressive study of a treatment currently available to patients. The aim of this trial is to show the treatment is able to reduce the progression of the condition and prevent related vision loss. Participants will receive a treatment injection in their effected eyes for 12 months. Principal Investigator Associate Professor Anthony Kwan.

READ THE KEY INCLUSION CRITERIA FOR DME STUDY


Choosing to participate in a clinical trial is an important personal decision. Talk with your GP, local health care professional and family members before deciding to join a trial. To learn more about any of these studies, you or your doctor may contact the study research staff on 07 3239 5000 or email:

For all studies, to enable our QEI Ophthalmologist to confirm diagnosis a referral from your Optometrist, General Practitioner or Ophthalmologist is required prior to registering your interest at the Queensland Eye Institute.